Sandu Pharmaceuticals Limited has made a regulatory filing to the Bombay Stock Exchange pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The disclosure concerns board appointments approved by members at the 41st Annual General Meeting held on Friday, September 11, 2026, conducted through Video Conferencing/Other Audio-Visual Means.
Key Appointments Approved:
1. Redesignation of Shri Balram Viswanathan (DIN: 10245195)
- Redesignated from Chairman and Non-Executive Independent Director to Chairman and Managing Director
- Effective date: July 11, 2026
- Term: 3 years
- Profile: B.Com., FCA, CPA (USA) with over 30 years of experience in financial services industry. Expertise includes Audit, Taxation, Compliance, Due Diligence, Mergers & Acquisitions Advisory, Valuation Services, Financial Control, Financial Planning, Regulatory Reporting, Business Analysis, Strategy, and Treasury and Risk Management.
- Relationship disclosure: Not related to any Director, Key Managerial Personnel, or Promoters of the Company
- SEBI status: Not debarred from holding director office by any SEBI order
2. Appointment of Dr. Neeti Madan Kapre (DIN: 06801264)
- Appointed as Non-Executive Independent Director
- Effective date: July 11, 2026
- Term: 5 years (not liable to retire by rotation)
- Profile: MBBS Gold Medallist (Indira Gandhi Government Medical College, Nagpur), M.S. (ENT) from K.E.M. Hospital, Mumbai, D.N.B. (ENT). Former Clinical Research Fellow, Head and Neck Services at TMH, Mumbai (August 2013 to August 2015). Participated in Global Fellowship Programme at Memorial Sloan Kettering Cancer Centre, New York. Extensive professional memberships including Founder Member of Indian Society of Thyroid Surgeons and Vidarbha Society of Head and Neck Oncology.
- Relationship disclosure: Not related to any Director, Key Managerial Personnel, or Promoters of the Company
- SEBI status: Not debarred from holding director office by any SEBI order